PetersALBuschurEOBuseJBCohanPDinerJCHirschIB.Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38(9):1687-1693. doi:10.2337/dc15-0843
2.
MussoGSabaFCassaderMGambinoR.Diabetic ketoacidosis with SGLT2 inhibitors. BMJ. 2020;371:m4147. doi:10.1136/bmj.m4147
3.
GoldenbergRMBerardLDChengAYY, et alSGLT2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis. Clin Ther. 2016;38(12):2654-2664.e1. doi:10.1016/j.clinthera.2016.11.002
4.
AtaFYousafZKhanAA, et alSGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort. Sci Rep. 2021;11(1):10293. doi:10.1038/s41598-021-89752-w
5.
YangSLiuYZhangS, et alRisk of diabetic ketoacidosis of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials. Front Pharmacol. 2023;14:1145587. doi:10.3389/fphar.2023.1145587
6.
BamgboyeAOOniIOCollierA.Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2-inhibitors: a review. Eur J Clin Pharmacol. 2021;77:651-657. doi:10.1007/s00228-020-03051-3
7.
NaranjoCABustoUSellersEM, et alA method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-245. doi:10.1038/clpt.1981.154
8.
WatsonKEDhaliwalKRobertshawS, et alConsensus recommendations for sick day medication guidance for people with diabetes, kidney, or cardiovascular disease: a modified Delphi process. Am J Kidney Dis. 2023;81(5):564-574. doi:10.1053/j.ajkd.2022.10.012
